Karl-Erik Andersson to Urologic Diseases
This is a "connection" page, showing publications Karl-Erik Andersson has written about Urologic Diseases.
Connection Strength
1.991
-
Andersson KE, Williams JK. Regenerative pharmacology in urology. Investig Clin Urol. 2017 03; 58(2):79-81.
Score: 0.500
-
Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011 Mar; 30(3):292-301.
Score: 0.329
-
Kurizaki Y, Ishizuka O, Imamura T, Ichino M, Ogawa T, Igawa Y, Nishizawa O, Andersson KE. Relation between expression of a(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2011 Feb; 45(1):15-9.
Score: 0.323
-
Roosen A, Chapple CR, Dmochowski RR, Fowler CJ, Gratzke C, Roehrborn CG, Stief CG, Andersson KE. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009 Nov; 56(5):810-9.
Score: 0.297
-
Andersson KE. Are female lower urinary tract symptoms alleviated by alpha-adrenoreceptor antagonists? Nat Clin Pract Urol. 2008 Nov; 5(11):586-7.
Score: 0.280
-
Lin WY, Andersson KE, Lin CL, Kao CH, Wu HC. Association of lower urinary tract syndrome with peripheral arterial occlusive disease. PLoS One. 2017; 12(3):e0170288.
Score: 0.126
-
Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Gravas S, Madersbacher S. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011 Oct; 60(4):784-95.
Score: 0.085
-
Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004 Jul; 84(3):935-86.
Score: 0.052